MedTrace Logo

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2012-03-06

Study results available
· View outcomes & findings →

Summary

To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema

Conditions

Interventions

DRUG

Aliskiren

300 mg once daily

DRUG

Placebo

Matching placebo once daily

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States
  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768040 on ClinicalTrials.gov